# Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma

> **NCT00185302** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 28 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
- **DRUG:** Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)

## Key facts

- **NCT ID:** NCT00185302
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2015-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185302, "Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00185302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*